A key FDA advisory panel just handed patients and integrative practitioners a rare win. But the agency still has the power to ignore it. Action Alert!
Listen to the audio version of this article:
THE TOPLINE
- An FDA advisory committee voted to recommend adding six peptides—BPC-157, MOTS-c, KPV, TB-500, Epitalon, and Semax—to the 503A Bulks List, potentially preserving prescription-based access through traditional compounding pharmacies.
- The vote defied FDA staff recommendations to reject every peptide reviewed and marked a significant shift from earlier committee decisions, but it is not final: the FDA can disregard the panel and must still act through formal rulemaking.
- The larger fight concerns the FDA’s use of drug-approval standards for compounded medicines, which could eliminate access to non-patentable therapies and drive patients toward unsafe gray-market products; ANH-USA plans to press the agency and may pursue legal action.
At a July 23-24 meeting, the Food and Drug Administration’s Pharmacy Compounding Advisory Committee (PCAC) voted to recommend that six peptides be added to the federal “503A Bulks List,” which would allow traditional compounding pharmacies to make them for patients with a valid prescription. The peptides are BPC-157, MOTS-c, KPV, TB-500, Epitalon, and Semax. The only peptide rejected by the committee was Emideltide.
PCAC voted in favor of these peptides despite FDA staff recommending that every peptide under review be rejected. This reversal was presumably the result of the recently remade PCAC committee that included clinicians who actually use these medicines in their practice. It is a positive sign for patient access, but we must continue to press the FDA to ensure a favorable outcome.
What Are Peptides, and Why Do We Need Them?
Peptides are short chains of amino acids. Some are already used in medicine. Others are used by integrative and functional medicine practitioners as part of personalized care plans. They show great promise for helping the body’s ability to heal from injuries as well as supporting a slew of other biological processes, including potentially extending lifespan.
It is crucial that these medicines get added to the 503A Bulk Drug List, or else patients will either lose access to these medicines entirely or be forced to seek them out on the grey market, where adulteration and impurities are rampant.
In order to be compounded, a substance must either 1) be a component of an approved drug, 2) have a United States Pharmacopeia monograph, or 3) be added to the 503A Bulk List. The signaling peptides we’ve been writing about do not satisfy criteria 1 or 2, so if they are not added to the Bulk Drug List, they cannot be made at compounding pharmacies. At earlier PCAC meetings, the committee followed FDA’s recommendation and voted to reject thymosin alpha-1 (Ta1), AOD-9604, CJC-1295, kisspeptin-10, ipamorelin, ibutamoren, and—wait for it—the amino acid L-theanine, as found in green and black tea.
Reversing this trend and voting in favor of key peptides like BPC-157 and epitalon is a breath of fresh air. We must remember, though, that PCAC is an advisory body and only makes recommendations; the FDA will follow up with a formal rulemaking and is not obliged to follow the committee’s votes. We could only find one instance where the FDA did not follow PCAC’s recommendation: when the committee voted to allow the compounding of tranilast but the FDA rejected it in its proposed rule. We shall see if the agency continues with this pattern or chooses to reject patient access to peptide bioregulators.
The Bigger Threat: Drug-Approval Standards for Compounded Medicine
FDA’s central objection appears to be the lack of the kind of large clinical trial evidence normally required for new drug approval to prove safety and efficacy.
But compounded medicines are legally distinct from FDA-approved drugs and are exempt from the new drug approval process when they meet the conditions laid out in federal law.
If FDA demands pharmaceutical-style evidence for every compounded substance, it can effectively wipe out access to many non-patentable or low-profit natural and integrative therapies. Why? Because no company is likely to spend hundreds of millions of dollars running drug-style trials for a substance it cannot exclusively own.
That creates a rigged system where compounded and personalized medicines face an impossible standard.
Access Does Not Mean Hype
ANH-USA supports patient access, practitioner judgment, and lawful compounding. That does not mean every peptide claim made online is proven. It does not mean consumers should buy peptides from questionable internet sellers or rely on influencer medicine.
In fact, one of the strongest arguments for lawful compounding access is safety. When FDA blocks legitimate access, demand does not disappear. Patients may turn to gray-market products of uncertain quality, strength, purity, or sterility.
A prescription-based compounding pathway can provide more oversight than the current “buyer beware” marketplace.
Consumers deserve honest information, real safeguards, and access to practitioners who can help them weigh risks and benefits. They do not deserve a system that drives health options underground.
Keep Up the Pressure
FDA still must decide whether to add these peptides to the 503A Bulks List through formal rulemaking.
ANH-USA is developing a petition urging FDA to use a legitimate scientific framework for evaluating peptides used in compounding. That means looking at the totality of available evidence, not pretending that compounded medicines should be judged exactly like mass-market patented drugs.
We will be watching closely to see whether FDA respects the advisory committee’s vote. If the agency once again places its hostility toward compounding ahead of patient access and practitioner judgment, ANH-USA will work to challenge that decision, including through legal action if necessary.
This vote was a meaningful step forward. But the fight for peptide access, personalized medicine, and health freedom is far from over.
Action Alert!
